# NeoCura

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neocura

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.neocura.com.cn
- Total disclosed funding: $117M
- Latest round: Series A (Dec 21, 2021)
- Investors on record: 7

## About

Based in Shenzhen, China and established in 2017, NeoCura is pharmaceutical company that focuses on tumor field based on RNA technology. The company has additional offices in Beijing, and Guangzhou. The company has established multi-omics big data collection platform, and multi-bioomics database. The company use artificial intelligence (AI) algorithm plus test data for in-depth drug target mining and automated drug design to develop innovative drugs. The company has over 30 invention patents, including 10 patents are foreign inventions. The company won the  2021 China's Most Potential Enterprise, and 2021 China's TOP10 AI/Computing Pharmaceutical Innovation Enterprise.

The company's R&D pipeline include tumor neoantigen vaccine, tumor microenvironment immunomodulation, and virus vaccine. The company self-developed artificial intelligence bio-information target mining platform, RNA drug platform, automated drug design, drug screening verification platform, multi-omics big data collection and analysis platform.

The company plans to promote the R&D progress of tumor neoantigen vaccine, tumor microenvironment immunomodulation, and virus vaccine. Moreover, the company will optimize the AI platform, building plant, and accelerating to promote the innovate drug clinical and commercialization.

## Funding rounds

- Series A, Dec 21, 2021, $79M — CDH Investments, PICC Capital Equity Investment, Shunxi Fund, Shenzhen Jiayin Fund Management
- Series A, Dec 23, 2020, $38M — IDG Capital, Alwin Capital, Shanhai Capital

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A
- Alwin Capital — Series A
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Series A
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series A
- PICC Capital Equity Investment (https://capitalatlas.ai/funds/picc-capital-equity-investment) — Series A
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series A
- Shenzhen Jiayin Fund Management — Series A